Skip to main content
. 2016 Mar;22(3):10.18553/jmcp.2016.22.3.209. doi: 10.18553/jmcp.2016.22.3.209

TABLE 3.

bDMARD and csDMARD Treatment Patterns by bDMARD Fill Status

All Patients (N = 373) Early Biologic Fillersa(n = 170) Late Biologic Fillersb(n = 59) Nonfillersc(n = 144) Late Biologic Fillers and Nonfillers Combined (n = 203)
Index bDMARD, n (%)
  TNFi 331 (88.7) 154 (90.6) 53 (89.8) 124 (86.1) 177 (87.2)
  Non-TNFi biologic 42 (11.3) 16 (9.4) 6 (10.2) 20 (13.9) 26 (12.8)
csDMARD use, n (%)
  Any 235 (63.0) 128 (75.3) 45 (76.3) 62 (43.1) 107 (52.7)
  Days -1 to 180 pre-index 216 (57.9) 121 (71.2) 38 (64.4) 57 (39.6) 95 (46.8)
  Days 0 to 30 post-index 135 (36.2) 78 (45.9) 22 (37.3) 35 (24.3) 57 (28.1)
  Days 31 to 180 post-index 187 (50.1) 100 (58.8) 36 (61.0) 51 (35.4) 87 (42.9)
Any injectable biologic DMARD during days 31-180 post-index, n (%)
  Yes 207 (55.5) 148 (87.1) 59 (100.0) 0 59 (29.1)
  No 166 (44.5) 22 (12.9) 0 144 (100.0) 144 (70.9)

abDMARD prescription filled within 30 days of index bDMARD.

bbDMARD prescription filled within 31-180 days of index bDMARD.

cbDMARD prescription not filled at all within 180 days of index bDMARD.

bDMARD = biologic disease-modifying antirheumatic drug; csDMARD = conventional synthetic disease-modifying antirheumatic drug; TNFi = tumor necrosis factor inhibitor.